Author(s):
Alchab Faten, Alshekh Ali, Rajab Maya
Email(s):
faten.alchab@tishreen.edu.sy , faten.alchab@manara.edu.sy , ali.alshekh@manara.edu.sy , maya.rajab@manara.edu.sy
DOI:
10.52711/0974-360X.2024.00595
Address:
Alchab Faten1*, Alshekh Ali2, Rajab Maya3
1Lecturer at Department of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy, Tishreen University, Latakia, Syria.
2Lecturer – Partial Time - at Department of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy, Manara University, Latakia, Syria
3Faculty of Pharmacy, Manara University, Latakia, Syria.
*Corresponding Author
Published In:
Volume - 17,
Issue - 8,
Year - 2024
ABSTRACT:
Acquired immunodeficiency syndrome (AIDS) is a chronic and potentially fatal transmissible disease caused by the Human Immunodeficiency Virus (HIV). Since its discovery in 1981, an estimated 85 million cases and 40 million AIDS related deaths have occurred worldwide. Among the two types of HIV, HIV-1 accounts for over 90% of reported cases. Throughout the years, multiple drugs have been approved for the treatment of AIDS. However, these drugs face many drawbacks such as toxic side effects, non-optimal pharmacodynamic profile and drug resistance due to virus mutation. This study aims to design novel potent HIV-1 protease inhibitors that overcome these drawbacks through molecular modelling methods. Pubchem database was screened for potential lead compounds. Results were filtered through two phases of ADMET and docking studies. Finally, the chosen lead compound was optimized through fragment replacement to obtain the novel inhibitors.
Cite this article:
Alchab Faten, Alshekh Ali, Rajab Maya. Design of Novel HIV-1 Protease Inhibitors with Favorable Oral Properties using a Molecular Modelling Approach. Research Journal of Pharmacy and Technology. 2024; 17(8):3836-2. doi: 10.52711/0974-360X.2024.00595
Cite(Electronic):
Alchab Faten, Alshekh Ali, Rajab Maya. Design of Novel HIV-1 Protease Inhibitors with Favorable Oral Properties using a Molecular Modelling Approach. Research Journal of Pharmacy and Technology. 2024; 17(8):3836-2. doi: 10.52711/0974-360X.2024.00595 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-8-43
REFERENCES:
1. The World Health Organization. 15 October 2023]; Available from: https://www.who.int/.
2. Hemelaar, J., et al., Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. Aids, 2006; 20(16): p. W13-23. https://doi.org/10.1097/01.aids.0000247564.73009.bc
3. Shao, Y. and C. Williamson, The HIV-1 epidemic: low- to middle-income countries. Cold Spring Harb Perspect Med, 2012; 2(3): p. a007187. https://doi.org/10.1101/cshperspect.a007187
4. The US National Institution of Health. 15 October 2023]; Available from: https://hivinfo.nih.gov.
5. Bandera, A., et al., Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr Opin Pharmacol, 2019; 48: 24-32. https://doi.org/10.1016/j.coph.2019.03.003
6. Ghosh, A.K., H.L. Osswald, and G. Prato, Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. Journal of Medicinal Chemistry, 2016; 59(11): 5172-5208. https://doi.org/10.1021/acs.jmedchem.5b01697
7. S. Ramasamy, et al., In-silico Ligand and Structure Based Design of HIV-1 Protease Inhibitors: Current Trends and Future Directions. Research Journal of Pharmacy and Technology, 2022; 15(4): 1477-2. https://doi.org/10.52711/0974-360X.2022.00245
8. Mebarka Tekha, Abdelkader Hadjsaid, and A. Douadi, Theoretical Studies of Molecular Structure, Drug Likeness and QSAR Modeling of some Carbocyclic Nucleosides against HIV-1. Research Journal of Pharmacy and Technology 2023; 16(9): 4257-5. https://doi.org/10.52711/0974-360X.2023.00697
9. Viol Dhea Kharisma, et al., Antiretroviral Effect Simulation from Black Tea (Camellia sinensis) via Dual Inhibitors Mechanism in HIV-1 and its Social Perspective in Indonesia. Research J. Pharm. and Tech, 2021; 14(1): 455-460. https://doi.org/10.5958/0974-360X.2021.00083.4
10. R. Kannadasan, I. Arnold Emerson, and M.S.S. Basha, Docking of HIV-1 with Neem using Autodock in Bioinformatics. Research J. Pharm. and Tech, 2017; 10(11): 3877-3880. https://doi.org/10.5958/0974-360X.2017.00704.1
11. Olga Nesterova, et al., Effect of N'-Benzyl Substituted Uracil and the Analogues on HIV-1 Inhibition. Research Journal of Pharmacy and Technology. 2021; 14(5): 2723-8. https://doi.org/10.52711/0974-360X.2021.00480
12. Blood, G.A.C., Human Immunodeficiency Virus (HIV). Transfus Med Hemother. 2016; 43(3): 203-22. https://doi.org/10.1159/000445852
13. Engelman, A. and P. Cherepanov, The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012; 10(4): 279-90. https://doi.org/10.1038/nrmicro2747
14. Weber, I.T. and J. Agniswamy, HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses, 2009; 1(3): 1110-36. https://doi.org/10.3390/v1031110
15. Tie, Y., et al., High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol. 2004; 338(2): 341-52. https://doi.org/10.1016/j.jmb.2004.02.052
16. Farady, C.J. and C.S. Craik, Mechanisms of macromolecular protease inhibitors. Chembiochem. 2010; 11(17): 2341-6. https://doi.org/10.1002/cbic.201000442
17. Lv, Z., Y. Chu, and Y. Wang, HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015; 7: 95-104. https://doi.org/10.2147/hiv.S79956
18. Boesecke, C. and D.A. Cooper, Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS, 2008; 3(6): 653-9. https://doi.org/10.1097/COH.0b013e328312c392
19. Ghosh, A.K., et al., Enhancing Protein Backbone Binding—A Fruitful Concept for Combating Drug-Resistant HIV. Angewandte Chemie International Edition. 2012; 51(8): 1778-1802. https://doi.org/https://doi.org/10.1002/anie.201102762
20. Koh, Y., et al., Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother, 2003, 47(10): 3123-9. https://doi.org/10.1128/aac.47.10.3123-3129.2003
21. Soham Pawar, et al., Molecular Docking using different Tools. Asian Journal of Pharmaceutical Research. 2023; 13(4): 292-6. https://doi.org/10.52711/2231-5691.2023.00053
22. Vishwajit S. Patil and P.A. Patil, Molecular Docking: A useful approach of Drug Discovery on the Basis of their Structure. Asian Journal of Pharmaceutical Research. 2023; 13(3): 191-5. https://doi.org/10.52711/2231-5691.2023.00036
23. Wensing, A.M.J., N.M. van Maarseveen, and M. Nijhuis, Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Research. 2010. 85(1): 59-74. https://doi.org/https://doi.org/10.1016/j.antiviral.2009.10.003
24. Diseases, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012-2023.
25. Benet, L.Z., et al., BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016. 101: 89-98. https://doi.org/10.1016/j.addr.2016.05.007
26. Lipinski, C.A., Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000; 44(1): 235-49. https://doi.org/10.1016/s1056-8719(00)00107-6
27. Lipinski, C.A., et al., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3): 3-26. https://doi.org/10.1016/s0169-409x(00)00129-0
28. Veber, D.F., et al., Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12): 2615-23. https://doi.org/10.1021/jm020017n
29. BIOVIA, D.S., Discovery Studio 2016, San Diego: Dassault Systèmes. 2016.
30. Shravani S. Pawar and S.H. Rohane, Review on Discovery Studio: An important Tool for Molecular Docking. Asian J. Research Chem. 2021; 14(1): 86-88. https://doi.org/10.5958/0974-4150.2021.00014.6
31. Bhagyashree L. Jejurikar and Sachin H. Rohane, Drug Designing in Discovery Studio. Asian J. Research Chem. 2021; 14(2): 135-138. https://doi.org/10.5958/0974-4150.2021.00025.0
32. The RCSB protein database. 19 October 2023]; Available from: http://www.rcsb.org/.
33. Berman, H.M., et al., The Protein Data Bank. Nucleic Acids Research. 2000; 28(1): 235-242. https://doi.org/10.1093/nar/28.1.235
34. Kuczera, K., J. Wiorkiewicz, and M. Karplus, CHARMM. Harvard University, 1993.
35. Kim, S., et al., PubChem 2023 update. Nucleic Acids Research, 2022. 51(D1): D1373-D1380. https://doi.org/10.1093/nar/gkac956
36. Bajusz, D., A. Rácz, and K. Héberger, Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? Journal of Cheminformatics. 2015; 7(1): 20. https://doi.org/10.1186/s13321-015-0069-3
37. Rao, S.N., et al., Validation Studies of the Site-Directed Docking Program LibDock. Journal of Chemical Information and Modeling. 2007; 47(6): 2159-2171. https://doi.org/10.1021/ci6004299
38. Gagnon, J.K., S.M. Law, and C.L. Brooks, 3rd, Flexible CDOCKER: Development and application of a pseudo-explicit structure-based docking method within CHARMM. J Comput Chem. 2016; 37(8): 753-62. https://doi.org/10.1002/jcc.24259
39. Kumar, R., Discovery of a new Drug: A Fundamental Review. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(3): 245-0. https://doi.org/10.52711/2231-5659.2022.00043
40. Dibyajyoti Saha and M. Hait, Lead Optimization: Research Pathways in Medicinal Chemistry. Asian J. Research Chem. 2011; 4(4).
41. Hansen, K., et al., Benchmark Data Set for in Silico Prediction of Ames Mutagenicity. Journal of Chemical Information and Modeling. 2009; 49(9): 2077-2081. https://doi.org/10.1021/ci900161g